Immediate Impact
13 standout
Citing Papers
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
2024 Standout
Works of David E. Janhofer being referenced
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| David E. Janhofer | 126 | 17 | 29 | 41 | 40 | 16 | 208 | |
| Michael Elmore | 61 | 25 | 43 | 22 | 40 | 14 | 150 | |
| Joana Martins | 106 | 10 | 10 | 67 | 7 | 29 | 216 | |
| Paula Valerie ter Wengel | 141 | 7 | 20 | 25 | 31 | 14 | 260 | |
| Marc Prablek | 143 | 14 | 11 | 39 | 31 | 21 | 246 | |
| Kenneth M. Crandall | 157 | 11 | 4 | 41 | 33 | 22 | 246 | |
| David J. Salvetti | 163 | 21 | 63 | 67 | 53 | 15 | 282 | |
| W.L.E.M. Hesp | 163 | 13 | 10 | 31 | 52 | 14 | 254 | |
| Thomas P. Lehman | 133 | 14 | 46 | 10 | 19 | 11 | 271 | |
| Laura S. Paré | 142 | 8 | 8 | 106 | 27 | 15 | 279 | |
| Anni Wong | 126 | 8 | 108 | 10 | 23 | 22 | 232 |
All Works
Loading papers...